Buying stocks whose share prices are in the hundreds or thousands of dollars can be tough for retail investors without big bankrolls. But several ETFs exist that solve that problem.

NEW YORK (TheStreet) -- Amazon (AMZN), Apple (AAPL) and Chipotle (CMG) are just three stocks that almost every investor wants to own. But popularity like that comes with a hefty price tag, which makes it difficult for average investors to buy more than a handful of those shares.

Owning just 100 shares of Amazon, for instance, would cost you nearly $43,000, based on Friday's closing price. That's almost a bargain compared to the more than $51,000 it takes to buy 100 shares of Regeneron Pharmaceuticals (REGN).

The good news is that there are plenty of exchange-traded funds with solid exposure to these pricey stocks. And they aren't expensive to own. So investors can use them to invest in the Amazons and Regenerons of the world without an excessive outlay of cash.

Consider the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE), where eight of the top 10 stocks trade for over $100 per share.

That group includes names like Biogen (BIIB) and Cramer favorite Regeneron, PBE's largest holding at a weight of nearly 5.9%. The PowerShares Dynamic Biotechnology & Genome Portfolio, which is home to nearly $557 million in assets, is up 14.8% this year.

The ETF closed just under $58 Friday and its 52-week high is almost $59. Sticking with the theme of accessing high-priced stocks via ETFs, for the health care industry, the Market Vectors Pharmaceutical ETF (PPH) also merits consideration.